Vortioxetine Hydrobromide Inhibits the Growth of Gastric Cancer Cells In Vivo and In Vitro by Targeting JAK2 and SRC

Scientists found that vortioxetine hydrobromide, an FDA-approved drug, was a dual tyrosine-protein kinase 2 (JAK2)/proto-oncogene tyrosine-protein kinase (SRC) inhibitor, and had inhibitory effects on cell proliferation of gastric cancer.